Resistance mutation

Outlook on the Worldwide Anti-viral Drug Industry to 2025 - Major Players and Strategy Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 20, 2020

The global anti-viral drug market is increasing due to the increasing prevalence of influenza across various countries around the world.

Key Points: 
  • The global anti-viral drug market is increasing due to the increasing prevalence of influenza across various countries around the world.
  • The increasing influenza prevalence around the world is a second major reason for the increasing demand for anti-viral drugs around the world.
  • On the basis of application type, the global anti-viral drug market is segmented by herpes antiviral drugs, hepatitis antiviral drugs, HIV antiviral drugs, influenza antiviral drugs, and other antiviral drugs.
  • The global anti-viral drug market segmentation based on the mechanism of action is done by nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others.

Technological Advances in the Anti-Viral Drug Therapy Market to Aid Treatment of COVID-19 Patients, Reports TBRC

Retrieved on: 
Thursday, May 14, 2020

Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.

Key Points: 
  • Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.
  • The use of certain existing anti-viral drugs for the covid-19 treatment is contributing to the growth of the anti-viral drugs market.
  • Increasing public-private funding for life science research globally is also expected to drive the growth of the global anti-viral drug therapy market.
  • Request A Free Sample Of The Anti-Viral Drug Therapy Market Report:
    The anti-viral drug therapy market is segmented by drug class into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.

New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020

Retrieved on: 
Wednesday, March 11, 2020

These data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2020 in Boston.

Key Points: 
  • These data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2020 in Boston.
  • Additional data presented at CROI provided further information on the potential utility of GS-6207 that support further development of the compound.
  • Results from a preclinical study evaluating the impact of resistance mutations on the in vitro antiviral activity of GS-6207 were also presented.
  • These promising early data are part of Gileads commitment to addressing the real-world needs of people living with HIV.

Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy

Retrieved on: 
Thursday, March 7, 2019

"At Janssen, we are committed to the ongoing research and development of innovative solutions to fight HIV across the continuum of care.

Key Points: 
  • "At Janssen, we are committed to the ongoing research and development of innovative solutions to fight HIV across the continuum of care.
  • Using heart, science and ingenuity, we are partnering with others and utilizing our scale with the aim to make HIV history."
  • Three patients (1 percent) who received the LA regimen developed CVF with subsequent identification of resistance mutations to one or both agents.
  • "This novel approach may help alleviate the burden often associated with daily oral treatment regimens and contribute to making HIV a smaller part of people's lives."